Physician profile
John Ray Martinez
NPI 1154352417
$1,596.32
in general payments reported to CMS, 2019-2025
22 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $107 · 2021: $87.22 · 2022: $138 · 2023: $324 · 2024: $94.59 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380 · Travel and Lodging: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.05 |
| Travel and Lodging | $195.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $350.46 | 2019-2022 | |
| Cook Medical LLC | $276.62 | 2023 | Cook |
| Mallinckrodt Enterprises LLC | $145.67 | 2019 | |
| Travere Therapeutics, INC. | $123.20 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $90.80 | 2019-2023 | Farxiga |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.83 | 2019 | |
| Akebia Therapeutics INC | $79.53 | 2020-2024 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $53.42 | 2020-2022 | |
| Horizon Therapeutics Plc | $53.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $48.86 | 2019-2024 | |
| Baxter Healthcare | $41.98 | 2022-2024 | Renal - Pd |
| Calliditas Therapeutics US INC. | $38.89 | 2025 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $32.21 | 2019 | |
| Opko Pharmaceuticals, LLC | $30.65 | 2019-2022 | |
| Ardelyx, INC. | $24.30 | 2024 | Ibsrela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.19 | 2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $22.59 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.22 | 2022 | |
| Daiichi Sankyo INC. | $15.01 | 2019 | |
| Medtronic, INC. | $13.70 | 2021 | |
| Angiodynamics, INC. | $13.42 | 2020 | |
| Glaxosmithkline, LLC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.